🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Some more 💰 slides from Day 2 #ASCO25 Breast cancer focus #bcsm

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

#ASCO25 Neoadjuvant or adjuvant in dMMR colon cancer? Looks like we’ll be discussing this at length today. Let’s start with this comparison👇

🌟🎓👏🧵 RCC Highlights @ #ASCO25 | Part 1 💬 Brilliant discussion by Tian Zhang, MD, MHS on 4 pivotal studies in advanced ccRCC OncoAlert 🔹 #Abstract4505 | CheckMate 214 – NIVO+IPI vs SUN (Marc Motzer et al) ✔️ 9-year follow-up ✔️ OS benefit in all IMDC groups ✔️ 108-mo OS: 31% vs 20%

The field of #HeadNeckCancer just got more interesting! #ASCO2025 #Plenary NIVO-POSTOP study was an important IIS for high risk HNSCC Positive DFS @ 3y But signal is primarily locoregional control! Stark contrast to KN689 Kudos to GORTEC Pierre Blanchard, MD Thoughts??

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer ASCO nejm.org/doi/full/10.10… NEJM OncoAlert If it improves survival in colon cancer, why not other cancers? What is the risk in recommending and educating our patients about the survival benefit of exercise!!

x.com/i/article/1929…

🫁 Resectable #NSCLC—an area where we have seen a lot of scientific developments! 💥 Big updates coming at #ASCO25 today! 👇 Here’s a refresher on where we stand today! 🔍 Let’s see how the treatment landscape may evolve 🌄, looking forward to a great session today!

🔥🚨OncoAlert Hot Off The Press Just published NEJM in conjunction with presentation ASCO #ASCO25 Results of #DeLLphi304 phase trial of: #Tarlatamab vs #Chemotherapy in 2nd Tx for advanced #SmallCell #LungCancer ✅#mOS: 13.6 vs 8.3 months (HR: 0.6) ✅More Improvement in

#ASCO25 SAVANNAH Phase II: savolitinib + osimertinib in EGFRm aNSCLC w/ MET amp or IHC3+ post-1L osi. 🔹ORR (BICR): 58% 🔹mPFS: 8.3 mo 🔹CNS PFS events: 36% (combo) vs 50% (savo+PBO) 🧠No new CNS mets in combo arm w/o baseline BM (0/13 vs 6/11). 📄 Annals: annalsofoncology.org/article/S0923-…

Immunotherapy time of day study; RANDOMISED; 1500hr cut off; massive PFS benefit ; massive OS benefit. #ASCO25 BTOG #LCSM

Impact of co-mutations on sotorasib efficacy in KRAS G12C NSCLC 🔺STK11 co-mut = ⬇️ ORR, PFS + OS, compared to TP53 & other co-mut 🤔 Small numbers 🤔 STK11 is bad news in KRAS 🤔 I would counsel pt, if I knew STK11 status 🤔 STK11 testing not available to all #LCSM #ASCO25

🚨 Is PAXG superior to mFOLFIRINOX in resectable pancreatic cancer? #ASCO25 📊 #CASSANDRATrial shows: ✅ 3-year EFS: 30% vs 14% ✅ Disease control: 95% vs 91% ✅ CA19-9 response: 88% vs 64% ✅ Fewer intra-op metastases #PancreaticCancer #Oncology #PAXG #FOLFIRINOX

These results will confirm the restriction on nivolumab approval to PD-L1+ve patients in Europe by EU Medicines Agency previously based on EFS data. #ASCO25 #LCSM

Results from #DeLLphi304 Phase 3 trial in NEJM #Tarlatamab vs Chemotherapy as 2L for advanced #SmallCell #LungCancer 🫁 ✅ mOS: 13.6 vs 8.3 months (HR 0.60) ✅ Grade ≥3 AEs: 54% vs 80% ✅ #CRS & #ICANS mostly grade 1/2 ‼️ This is practice changing and practice confirming

Long-term outcomes and OS for zanidatamab + CTx in HER2+ mGEA: 4-year follow-up #ASCO25 🔎Phs-2 👉ORR 76 %m DoR 18.7 mo 👉mPFS 12.5 mo 👉mOS 36 mo 👉Manageable safety 👉95% concordance btw ctDNA & IHC 🧐 strong efficacy signal, phase-3 data awaited ESMO - Eur. Oncology

x.com/i/article/1931…

New review on urothelial carcinoma highlights therapeutic & diagnostic approaches in the perioperative setting, emphasizing patient‐centered & individualized care. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Wesley Yip Salvador Jaime-Casas, MD Anjaney Kothari Domenique Escobar, MD 👩🏽‍⚕️🧜🏽‍♀️ Anne Schuckman Jonathan Rosenberg MD

Real-world data on 1323 EGFR+ NSCLC pts on 1L osimertinib: • Median OS: 28.6 mo • High-risk pts:  - TP53: 25.7  - Brain mets: 24.3  - Liver mets: 19.3  - ECOG ≥2: 18.1 This isn’t good enough. Patients & families deserve more. sciencedirect.com/science/articl…

How to improve outcome in advanced ovarian epithelial cancer post 1st line chemotherapy and sx ? Add IO or parp inhibitors or both or none ? Money slide to summarize all 4 new trials in this space. Taken from #ASCO25 ASCO Kate Sears OncoAlert